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Abstract 
 Cuprizone is a copper chelator that induces demyelination in the central nervous system 
when fed to mice. This compound is thought to target Complex IV and disrupt mitochondrial 
metabolism leading to loss of myelin-producing oligodendrocytes. In this proposal, we further 
examine the chemical and toxicological properties of cuprizone. Immunofluorescence imaging 
and microarray data on MO3.13 cells treated with cuprizone revealed the possibility of 
alterations in lysosomal function, as well as mitochondrial disruption via mTOR and Electron 
Transport Chain (ETC) related pathways. Cell viability assays conducted suggest that addition of 
Branched-Chain Amino Acids, most commonly used from literature, leucine, can increase cell 
vitality after being treated with cuprizone. Additional studies examined the solubility of 
cuprizone and interaction with zinc. Taken altogether, this experiment reveals that cuprizone 
affects lysosomal and mitochondrial function, and provides insight into leucine supplementation 
at an attempt to rescue cells from neurotoxicity.    
Introduction 
Myelin Sheath Function 
 
The myelin sheath plays a vital role in the insulation and conductivity of nerve impulses 
(Figure 1).1 Myelin is primarily composed of lipids, including membrane-associated 
phospholipids and cholesterol, and is produced by glial cells known as oligodendrocytes. 
Oligodendrocytes reside in close proximity with the neuron where they extend and wrap their 
cell process around an axonal segment. Myelin destruction is seen in autoimmune diseases such 
as multiple sclerosis (MS), in gene disorders, and after traumatic brain injury.2 Demyelination 
results in the loss or slowing of nerve impulses and axonal degeneration leading to clinical 
symptoms such as motor and cognitive dysfunction. 
   
 
Figure 1. Nerve cell shown in blue insulated by myelin sheath produced by mature 
oligodendrocytes shown in green. 
 
 The Human Oligodendrocytic Cell Line (MO3.13) is used as a model to study 
oligodendrocyte function in vitro (Figure 2).3 MO3.13 cells exhibit premature glial cell 
characteristics and can be induced to differentiate into mature myelin-producing 
oligodendrocytes or astrocytes.3 These cells are classified as oligodendrocyte precursor cells 
(OPCs), and exhibit neuronal stem cell properties.4  
 
Figure 2. Bright field image of confluent MO3.13 cells at 10x magnification. 
 
The capability of OPCs to differentiate via a stimulus into mature oligodendrocytes poses 
great possibility for repair of the CNS from both autoimmune and traumatic injury.4 The MO3.13 
cell line will be used as a model in this experiment to study lysosomal function and leucine 
supplementation from toxicity in the CNS. 
   
 
Chelation Properties and Toxicity of CPZ 
 
Cuprizone (CPZ), as seen in Figure 3, can act as a copper chelator and has been shown to 
disrupt mitochondrial function in vitro and in vivo.5 The chelating ability of CPZ has primarily 
been studied in solution with the absorbance of the Copper-CPZ complex at approximately 600 
nm, giving the solution a deep blue color.7 However, the chelating abilities of CPZ in vitro and in 
vivo have been incompletely defined. Introduction of CPZ has also been linked to altered zinc 
homeostasis and it is not known if CPZ chelates zinc or other metals along with copper, and if 
so, if CPZ has a higher affinity for zinc than copper.8  
 
Figure 3. Chemical structure of cuprizone (CPZ) (Chemdraw Professional). 
 
In order to dissolve CPZ into cell media, a solvent such as ethanol (EtOH) along with 
heating and mixing is needed.12 Few solubility studies have been done on CPZ in cell media. 
Two different manufactured CPZ products will be used throughout this experiment to determine 
whether or not there is a difference between them. These two CPZ powders come from Sigma 
Aldrich (St. Louis, MO) and Gojira (Bedford Heights, OH) The chelating properties of CPZ to 
zinc and copper will be tested in this experiment, along with further experimentation on CPZ 
solubility. 
   
Studies have shown that cuprizone (CPZ) feeding be used as a model in mice to study the 
processes of demyelination and remyelination as this compound induces loss of myelin in the 
corpus callosum, hippocampus, and cerebellar peduncles.6 The pathology induced by potential 
copper chelation in the body is complex. One idea is that CPZ binds all available copper, causing 
a deficiency of copper for oxidative phosphorylation and antioxidant activity.9 The terminal 
electron acceptor in the electron transport chain (ETC) is oxygen, which receives electrons from 
Cytochrome C Oxidase (COX) and is reduced to water. COX contains two copper binding sites, 
allowing for the enzyme to participate in redox activity.10 The redox capability of copper also 
allows it to help reduce Reactive Oxygen Species (ROS) by accepting electrons.9 Through said 
mechanism of copper chelation, CPZ induces toxicity.11 Oxidative phosphorylation occurs in the 
mitochondria, along with the localization of many antioxidant enzymes due to the high risk of 
ROS via the ETC. From this, we predict that the physiology of the mitochondria would be 
perturbed by the introduction of CPZ. 
mTOR Interactions with Branched Chain Amino Acids  
 
The Branched Chain Amino Acids (BCAAs), which include leucine, valine and 
isoleucine can be broken down for quick energy use by the cell.13 The process of degradation of 
BCAAs starts with a transamination followed by a decarboxylation. After this decarboxylation, 
each BCAA is broken down by different, but similar, mechanisms. The end products for the 
breakdown of BCAAs include oxidizable substrates such as acetyl CoA and acetoacetate.13 In 
addition to serving as an energy source, leucine can also activate protein synthesis through 
signaling by the Mammalian Target of Rapamycin complex (mTOR or mTORC). mTOR is a 
protein complex that is involved in promoting anabolic reactions. When there are nutrients 
available in the cell, mTOR signals for synthesis of proteins. When mTOR is active, it 
   
phosphorylates, thus inactivating, the protein ULK1 which promotes autophagy, a process by 
which cell components are degraded (Figure 4).14 
 
Figure 4. Proposed mTOR complex (mTORC) signal cascade upon addition of CPZ and 
Leucine. 
 
Swelling in the lysosomes is one of the features that cells undergoing autophagy 
exhibit.15 Lysosomes contain degradative enzymes such a proteases that break down the cell 
during autophagy. Previous experiments have found that excessive ROS generation by CPZ may 
induce pathological protein misfolding which may lead to the unfolded protein response and the 
activation of autophagy.16 This experiment will test three hypothesis: 1) Introduction of CPZ will 
cause lysosomal swelling, 2) CPZ induces dysfunction in both lysosomal and mitochondrial 
pathways, and 3) Leucine supplementation will reverse or decrease the toxic effects of CPZ. To 
test these hypothesis, microarray data of mitochondrial and lysosomal pathways will be analyzed 
from MO3.13 cells treated with CPZ for 6 hours and 9 hours compared to control untreated 
MO3.13 cells. Cell viability assays will be conducted to test whether or not leucine 
supplementation effects CPZ toxicity on MO3.13s. Lastly, fixed cell imaging on MO3.13 cells 
   
treated with CPZ using two lysosome probes, C10 and C11, will reveal lysosomal morphology 
upon introduction of CPZ. 
Materials and Methods 
Safety considerations for methods can be found in Appendix 1. 
Cell Culture 
 
The MO3.13 human oligodendrocyte precursor cell line from CELLutions Biosystems 
Inc. (Burlington, Ontario, CA) was kept in a liquid nitrogen dower until needed for culture. To 
thaw, a 1 mL tube containing a cell line was taken from the dower and kept at room temperature. 
Once at room temperature, the cell solution and 5 mL of Dulbecco’s Modified Eagle Medium 
(DMEM) with 10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin (P/S) were added 
to a T25 flask. The flask was placed in the incubator at 37°C with 5% CO2. Once the cells grew 
above 70% confluency in the T25 flask, they were split and plated into T75 flasks. To split the 
cells, the media was first removed from the flask. The cells were washed with 1X phosphate 
buffered saline (PBS). After gently shaking the flask, the PBS was removed. To remove the cells 
from the flask 2 mL of protease, trypsin EDTA, was added and let sit for no more than 3 
minutes. The trypsin is then diluted with 3 mL DMEM and transferred to a 15 mL conical tube. 
The cell solution was centrifuged at 1000 xg at 4°C for 10 minutes. Following centrifugation, the 
supernatant is aspirated and the pellet is re-suspended into new DMEM with 10% FBS and 1% 
p/s. This can either be directly aliquoted into cell culture flasks for maintenance of cell line, or 
counted and aliquoted to various cell experiments.  
Cell counts were determined as follows, the newly suspended cell solution from splitting 
is mixed either by vortexing or inverting. A 20 µl aliquot of cell solution is mixed by tittering 
with 80 µL of Trypan Blue, which stains dead cells blue. The solution is administered into a 
   
hemocytometer which is then placed under a bright field microscope. The hemocytometer 
contains four grids in which the cells are counted. The average cell count across the 4 grids is 
used in the calculation to find total cells per milliter: 
(Average cell count) x (104) x (Dilution factor, 5) = cells/mL 
After the total cells/mL was calculated, M1V1 = M2V2 calculations were conducted to achieve a 
specific number of cells/well for given experiments. 
CPZ Chelation 
To test CPZ chelation with copper and zinc, the following solutions were prepared. Stock 
CPZ solutions for both Sigma Aldrich and Gojira CPZ were prepared at 2 mM in 100% EtOH. 
The solutions were covered by foil to inhibit rapid evaporation. Stock copper solution was 
prepared by dissolving copper sulfate, CuSO4, into nanopure water at 1 mM. Stock zinc solution 
was prepared by dissolving zinc perchlorate, Zn(ClO4)2, at 1 mM in nanopure water. After all 
stock solutions were made, the chelation solutions were prepared: 10 mL of 2 mM CPZ was 
mixed with 10 mL of 1 mM CuSO4 and adjusted to pH 8 with 1 M NaOH and absorbance was 
measured. Afterwards, 1 equivalent of Zn(ClO4)2 was added, absorbance was measured, then 3 
equivalents of Zn(ClO4)2 was added and absorbance measured again. The other chelation 
solution was made by adding 10 mL of 2 mM CPZ with 10 mL of 1 mM Zn(ClO4)2, absorbance 
was measured, then pH adjusted to 8 and absorbance was measured again. Lastly, 1 equivalent of 
CuSO4 was added and absorbance measured. 
CPZ Solubility 
Stock solutions of CPZ were prepared and diluted to various concentrations depending on 
the experiment. CPZ powder purchased from Sigma Aldrich (St. Louis, MO) and Gojira 
   
(Bedford Heights, OH) was weighed on a scale, added to ethanol and diluted in dH2O, PBS or 
DMEM to reach final volume. The solution was placed in a water bath at 37°C and periodically 
vortexed until the powder went into solution. The solubility experiments followed the same 
protocol. Initially, to analyze the solubility of CPZ, many solutions were made varying in 
concentration, percentage of EtOH, and type of media. The types of media used were DMEM 
10% FBS 1% p/s, DMEM 1% p/s (no serum) and Hank’s Balanced Salt Solution (HBSS). The 
concentrations of CPZ were 15 mM, 25 mM and 40 mM. The percentages of EtOH were 20%, 
30% and 50%. A total of 27 CPZ solutions were made. The solutions were prepared according to 
Table 1. This represents the solutions made for one type of media, therefore Table 1 was made 
in triplicate using each type of media once.  
Table 1. Solution recipes for CPZ solubility made in 5 mL of media. Each solution was made 
once with each media. 
 15 mM CPZ 25 mM CPZ 40 mM CPZ 
20 % EtOH 20.9 mg CPZ 
1 mL EtOH 
4 mL Media 
34.8 mg CPZ 
1 mL EtOH 
4 mL Media 
55.7 mg CPZ 
1 mL EtOH 
4 mL Media 
30% EtOH 20.9 mg CPZ 
1.5 mL EtOH 
3.5 mL Media 
34.8 mg CPZ 
1.5 mL EtOH 
3.5 mL Media 
55.7 mg CPZ 
1.5 mL EtOH 
3.5 mL Media 
50% EtOH 20.9 mg CPZ 
2.5 mL EtOH 
2.5 mL Media 
34.8 mg CPZ 
2.5 mL EtOH 
2.5 mL Media 
55.7 mg CPZ 
2.5 mL EtOH 
2.5 mL Media 
 
Once all solutions were prepared, they were placed in the water bath at 37°C with 
frequent inversions. Images of the solutions were taken after an hour. A second CPZ solubility 
test was conducted following the results of the MTT assay to try to reduce the percentage of 
EtOH needed to dissolve the CPZ. This test consisted of 10 mM CPZ 10% EtOH and 10 mM 
CPZ 5% EtOH. These two solutions were prepared and placed in the water bath with sonication 
   
with frequent vortexing. Images were taken of the solutions after 3 hours. All solutions were 
prepared in a total of 5 mL of media. 
CPZ Microarray 
To determine if mitochondrial and lysosomal pathways were perturbed by CPZ toxicity, a 
microarray study was conducted. Stock CPZ solution was prepared at 1 mM 3% EtOH and was 
added to MO3.13 cells. After treatment of 6 and 9 hours along with a control group of no 
treatment, the RNA was isolated with trizol and normalized samples were run in triplicate on the 
Affymetrix human microarray. The data from the microarray was analyzed to determine 
pathology of mitochondrial and lysosomal function when introduced to CPZ. 
Leucine Supplementation MTT Assay 
Living cells will actively reduce yellow colored MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide) to formazan crystals due to the presence of NADPH 
oxidoreductases found in viable cells. This reaction produces a color change from yellow to 
purple, which can be quantified using a plate reader by taking an absorbance value between 500-
600 nm. The amount of MTT reduced, thus the darkness of the purple, correlates with the 
viability of the cell sample. MO3.13 cells were split and counted to plate 72,000 cells/well in a 
96-well plate. The cells were suspended in DMEM 10% FBS 1% p/s and added to each well then 
placed in the incubator to adhere overnight. Stock CPZ solution was made at 10 mM 30% EtOH 
and diluted to 1 mM 3% EtOH for treatment. The CPZ solution was added to the 96 well plate 
following Table 2 and the plate was placed in the incubator overnight.  
 
 
   
 
Table 2. Treatment on MO3.13s for MTT assay. Each row represents 12 wells (n=12). All 
solutions were made in DMEM 10% FBS 1% p/s. 
 Row 
1 1 mM CPZ, 0.8 mM Leucine, 3% EtOH 
2 1 mM CPZ, 0.6 mM Leucine, 3% EtOH 
3 1 mM CPZ, 0.4 mM Leucine, 3% EtOH 
4 1 mM CPZ, 0.2 mM Leucine, 3% EtOH 
5 1 mM CPZ, 3% EtOH 
6 3% EtOH (Vehicle)  
7 No Treatment (Control) 
 
The following day, stock leucine solution was prepared at 5 mM in DMEM 10% FBS 1% 
p/s then diluted into DMEM 10% FBS 1% p/s to obtain the following treatment concentrations: 
0.2 mM, 0.4 mM, 0.6 mM, and 0.8 mM. The leucine solution was added to the 96 well plate 
following Table 2, then the plate was placed in the incubator overnight. The MTT assay was 
conducted the following day by thawing stock 5 mg/mL MTT solution from the freezer and 
adding 20 µL to each well. The plate was the placed in the incubator for 3.5 hours. After 
incubation the plate was centrifuged at 1000 xg for 10 minutes. The media was removed making 
sure not to remove any crystals. After the media was removed, 150 µL of MTT solvent was 
added to each well, followed by covering the plate in foil. The plate was placed on the orbital 
shaker for 15 minutes on low speed. Absorbance was read at 590 nm with a reference filter of 
620 nm using the Spectramax M2 Plate Reader. 
Immunofluorescence 
Microscope slide coverslips were cleaned with ethanol and placed one per well into a 6-
well plate. A 1 mL aliquot of Poly-L Lysine (PLL) was taken from the freezer and set in the 
hood to thaw. The PLL was diluted into 9 mL of HPLC grade water and 1 mL was added onto 
   
each coverslip in each respective well making sure to fully cover each coverslip to further 
increase cell adherence. The 6-well plate was set for at least 1 hour before removing. Once the 
PLL was removed, the coverslips were washed a few times with HPLC grade water and set to 
dry in the hood. 
For the lysosome imaging, DMEM F-12, 1% p/s was used. This no-serum media was 
used to ensure that no interactions took place between the FBS, the lysosomal probe and the 
CPZ. Cells were split and counted as explained. From the results of the cell count, an aliquot of 
the cell solution was added to DMEM F-12, 1% p/s to reach the final concentration of 106 
cells/well. This solution was inverted before pipetting 3 mL of cell solution per well into the 
coated 6-well plate. The 6-well was placed in the incubator overnight to allow for the cells to 
adhere to the coverslips. 
Stock CPZ solutions were individually prepared using both Gojira brand CPZ and Sigma 
Aldrich (SA) brand CPZ the prior day and were placed in the incubator overnight. The 10 mM 
stock solutions in 5% EtOH were prepared by weighing 13.9 mg of CPZ and placing it into a 15 
mL conical tube along with 250 µL of EtOH and 450 µL of DMEM F-12, 1% p/s. The solutions 
were heated and sonicated with vortexing every 15 minutes. After 3 hours, the CPZ fully 
dissolved into solution. The vehicle solution was prepared by adding 250 µL of EtOH into 450 
µL of DMEM F-12, 1% p/s and inverting. The stock CPZ solutions and vehicle were diluted to 2 
mM 1% EtOH for treatment. The cells were treated according to Table 3. Both the C10 and C11 
probes generously provided by Dr. Yi Pang’s laboratory were tested using Sigma Aldrich CPZ. 
The C11 probe was also tested using Gojira CPZ. After treatment, the plate was placed in the 
incubator overnight. 
 
   
 
 
 
Table 3. Treatment of MO3.13 for lysosomal imaging. 
No Treatment (Control) 2 mM SA 
1% EtOH 
1% EtOH (Vehicle) 
2 mM Gojira  
1% EtOH 
2 mM SA 
1% EtOH 
1% EtOH (Vehicle) 
 
After treatment, the coverslips were fixed for cell imaging. For fixing cells, 4% 
paraformaldehyde (PFA) was prepared.  PFA was made in the hood by weighing 1 g of PFA 
powder (Sigma Aldrich) and adding it to 15 mL of 1X PBS. This solution was heated to 60°C 
while stirring until the powder was dissolved. The pH was adjusted to 7.4 with additions of 1 M 
NaOH. 1o mL PBS was then added to reach the final volume of 25 mL and the solution was 
filtered through a 45 µm syringe filter and stored in a 50 mL conical tube until use. Once PFA 
was prepared, the treated 6-well plate was aspirated to remove the cell media and 2 mL of PFA 
was added to fix the cells for 10 minutes. The PFA was then removed and the cells were washed 
twice with 1 mL of PBS per well. The following steps occurred with all lights off; The C10 and 
C11 lysosome probes were weighed and added to 1 mL each of DMSO to attain a 10 mM solution 
(5.72 mg of C10 and 5.42 mg of C11). To dilute to treating concentration of 1 µM, 1.5 µL of each 
probe was added to 15 mL of PBS. The solutions were inverted to mix and then 1 mL was added 
to each well. After 30 minutes the solution was aspirated off and the cells were washed 2 times 
with PBS. To stain the nuclei, DAPI solution was made by diluting a 1 mL aliquot of stock DAPI 
in 10 mL of PBS which was then added in 1 mL aliquots to cover each well for 5 minutes. The 
DAPI solution was then removed and the cells were washed with PBS 2 times before washing 
with HPLC grade water for 10 minutes. The coverslips were left to sit in the water under the 
   
hood until mounting. To mount the coverslips onto microscope slides, a drop of flouromount 
aqueous mounting medium was applied to the microscope slide. The coverslips were removed 
from the wells using sterile tweezers and were placed face down onto the slides where the 
mounting medium was applied. The coverslips were gently laid onto the slides to prohibit 
bubbles from forming and to create a proper seal. Once placed onto the slides the coverslips were 
not moved so that the cells stayed intact. After all coverslips were mounted to the slides, the 
slides were covered in foil and left in the refrigerator to dry for 24 hours. Once dry, clear nail 
polish was applied around the edges of the coverslips to complete the sealing process. Once 
sealed the slides were wrapped in foil and stored in the refrigerator until imaging. 
Fixed microscope slides were imaged with Nikon A1 Plus Confocal Microscope in Dr. 
Konopka’s lab at both 60x and 100x magnification. The excitation lasers were set to 405 nm for 
C10 and C11 lysosome probes, and DAPI. The emission filter was set from 640 nm to 715 nm for 
the lysosome probes and 425 nm to 475 nm for DAPI. 
Results and Discussion 
Cuprizone Chelation and Solubility: 
Both Gojira CPZ and SA CPZ were added to copper and zinc to determine the chelating 
properties of CPZ. There were no significant differences in chelation between the Gojira CPZ vs 
the SA CPZ. Unbound CPZ absorbs around 250 nm (Figures 5-7).  
   
 
Figure 5. Cumulative graph of both CPZ samples showing absorbance of CPZ solutions with 
zinc and copper. 
 
It has been proven that CPZ chelates copper, in which the complex has an absorbance 
around 600 nm. All solutions made with only copper and CPZ had a maximum intensity of 1 at 
600 nm, indicating that CPZ chelated copper. All solutions made with zinc and CPZ only had an 
absorbance reading at 250 nm, suggesting that there was no interaction between the zinc and 
CPZ (Figures 5- 7).  
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Figure 6. Sigma Aldrich CPZ chelation with zinc and copper. 
 
The solutions with both copper and zinc had a decreased intensity at 600 nm which 
suggests that there may be interactions between the zinc and copper, the zinc and CPZ, or both 
that perturbs CPZ from chelating to copper. From this data we confirmed that CPZ readily 
chelates copper, CPZ does not chelate zinc, and that further analyzation with mass spectrometry 
can be done to determine the interactions between CPZ, zinc and copper when all added to the 
same solution. 
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Figure 7. Gojira CPZ chelation with zinc and copper. 
 
CPZ Solubility 
There were a total of seven CPZ solutions from the solubility study that went into 
solution (Table 4). Of these solutions, the ones with the lowest concentration (15mM) and 
highest % EtOH (50%) went into solution the easiest, however this was expected. There were 
eight solutions that dissolved, but precipitated within 5 minutes after mixing (Table 4). The other 
thirteen solutions did not go into solution (Table 4). 
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Table 4. Results from first CPZ solubility experiment. NS is DMEM no-serum. 
IN SOLUTION FELL OUT < 5 MIN NOT IN SOLUTION 
15 mM 50% EtOH in DMEM 15 mM 30% EtOH in DMEM 15 mM ≤ 30% EtOH in HBSS 
40 mM 20% EtOH in HBSS 25 mM 50% EtOH in DMEM 25 mM ≤ 30% EtOH in DMEM 
15 mM 20% EtOH in HBSS 40 mM 20% EtOH in NS 25 mM ≤ 50% EtOH in HBSS 
15 mM 20% EtOH in NS 15 mM 30% EtOH in NS 40 mM ≤ 50% EtOH in DMEM 
25 mM 20% EtOH in NS 25 mM 30% EtOH in NS 40 mM ≤ 50% EtOH in HBSS 
15 mM 50% EtOH in HBSS 25 mM 50% EtOH in NS 40 mM ≤ 50% EtOH in NS 
15 mM 50% EtOH in NS   
 
 All HBSS solutions had a lot of foam after shaking, and overall, the no serum solutions had the 
best results. This first solubility experiment showed that CPZ can be dissolved into media. The 
second solubility experiment took into account the results from the first experiment, and added 
new steps to improve solubility. The solutions were left to sit longer in the incubator (3 hours), 
sonication was added, and no-serum media was used since it had the best results in the first 
solubility experiment. The CPZ went into solution for both Gojira CPZ and Sigma Aldrich CPZ 
in the second experiment (Figure 8). 
 
Figure 8. CPZ solutions that fully dissolved with the two lowest percentages of EtOH (10% and 
5%). 
   
This suggests that CPZ needs a lot of time and agitation to fully dissolve into solution, 
more so than what was done in the first experiment. Heat and sonication are also needed to 
dissolve CPZ. Finally, using no-serum DMEM mediates the process as well. For following 
experiments that used CPZ solution, the 10 mM CPZ with 5% EtOH in DMEM no-serum recipe 
was used since it contained the least amount of EtOH and had the best solubility results. 
CPZ Microarray 
After receiving the data from the microarray, the lysosomal and mitochondrial pathways 
were examined for both the 6 hour and 9 hour treatment of CPZ. Overall, there was more 
dysfunction with the 6 hour treatment than the 9 hour treatment, suggesting that cells are 
undergoing apoptosis at 9 hours and are shutting off pathways. To verify this, a time study can 
be done at 1 hour, 2 hours, 6 hours, 9 hours and 12 hours to evaluate CPZ toxicity vs time. Many 
mitochondrial pathways such as fatty acid oxidation, ETC and mitochondrial fusion were all 
effected by CPZ at 6 hours of treatment (Figures 9 and 10).  
   
 
Figure 9. The overall mTOR pathway was affected by CPZ at 6 hours. Image was created by 
Affymetrix transcriptome analysis software using the CPZ microarray data.  
 
The ETC complex 2 protein succinate dehydrogenase complex subunit D (SDHD), and 
multiple cytochrome proteins important in transferring electrons were effected by CPZ. This 
supports the hypothesis that CPZ toxicity acts through mitochondrial ROS and later impacts 
protein metabolism. Along with mitochondrial dysfunction, lysosomal and mTOR dysfunction 
were also recorded in the 6 hour CPZ treatment (Figure 9). 
   
 
Figure 10. Disruption of transcription of ETC subunits by CPZ at 6 hours. Image was created by 
Affymetrix transcriptome analysis software using the CPZ microarray data. 
 
 Both ULK1 and ULK2 have significant disruption in the 6 hour treatment, along with 
VMP1, another gene involved in autophagy. Many mTOR related genes were also disrupted, 
such as PTEN, PDK1 which directly phosphorylates AKT, and RHEB. The 9 hour CPZ 
microarray data showed significant disruption in ULK2, similar to ULK1 both of which involved 
in autophagy (Figure 11).  
   
 
Figure 11. Disruptions in autophagy pathway after 9 hours of CPZ toxicity. Image was created 
by Affymetrix transcriptome analysis software using the CPZ microarray data. 
 
There was also significant dysregulation in mTOR related pathways, one of these genes 
coding for the protein Growth Factor Receptor Protein 10 (GRB10) which is involved with 
signal transduction via receptor tyrosine kinase pathways (Figure 12).17 Other proteins affected 
in the mTOR pathway after 9 hours of CPZ treatment included EIF4G1 involved in protein 
translation and LAMTOR3, a late endosomal and lysosomal adaptor protein (Figure 12).18,19  
   
 
Figure 12. CPZ disruption of mTOR pathway after 9 hours. Image was created by Affymetrix 
transcriptome analysis software using the CPZ microarray data. 
 
All of these genes code for proteins related to signal transduction, suggesting that CPZ 
disrupts normal cellular function and induces autophagy. Overall, from this data, we suggest that 
CPZ causes mitochondrial and lysosomal dysfunction, and that the disruption of these pathways 
are linked through CPZ interference with mTOR signaling.  
Leucine Supplementation MTT Assay 
Many MTT assays were conducted for this experiment with mixed results. Most of the 
assays resulted in the vehicle, CPZ, or both killing the cells. Leucine supplementation did not 
significantly reverse CPZ toxicity in the assays that were done. From the results gathered, the 
data suggests that addition 0.2 mM leucine was most successful in rescuing cells from CPZ 
(Figure 13). The cells treated with CPZ only had around 55% viability. The vehicle was 3% 
   
EtOH which had a viability of around 85% compared to the untreated cells (Figure 13). This 
suggests that the EtOH added along with the CPZ does not effectively kill cells for this given 
assay. As treatment concentration of leucine increased past 0.2 mM to 0.4 mM, 0.6 mM and 0.8 
mM, the viability had no significant change after a drop from 60% viability at 0.2 mM to 45% 
viability for the latter treatments (Figure 13).  
 
Figure 13. Cell viability after cell rescue experiment with varying concentrations of leucine 
added to CPZ affected cells. Vehicle represents EtOH without CPZ. Cells represents no addition 
of treatment. 
 
The error bars on this graph are large, which means that the data may not be significant, 
however this assay provided good suggestions as to where to take this project in future 
experiments. Allowing for CPZ to effect cells for longer than 24 hours may decrease variation in 
results. Also treating with leucine at different concentrations such as 0.05 mM, 0.1mM, 1 mM, 
1.5 mM and 2 mM would help focus the most effective treatment concentration for leucine. As 
mentioned previously, after running the assays, it was discovered that CPZ could be dissolved in 
EtOH at 1% final EtOH treatment concentration which would also assure that the vehicle is not 
 
   
killing the cells. Overall, leucine supplementation is likely to affect CPZ toxicity however further 
experiments will have to be conducted to confirm this hypothesis. 
CPZ Induced Lysosomal Imaging: 
To determine morphology of lysosomes during CPZ toxicity, C10 and C11 lysosomal 
probes provided by Dr. Pang’s lab were used to target lysosomes via fluorescent imaging. Both 
probes were verified to target lysosomes, however it was observed that the probes may have 
targeted nuclear proteins as well. Originally, the C10 probe was not yet verified to work in fixed 
imaging. This experiment proved that the C10 probe was successful in targeting lysosomes 
following a fixed imaging protocol. The C11 probe was already verified to work, and it did in this 
experiment. Along with the lysosomal probes, DAPI was used to stain the nuclei to verify 
location and overall health of the cell. The cells treated with only EtOH for both C10 and C11 
probes exhibited more distribution of lysosomes throughout the cell (Figures 14 and 15). 
   
Figure 14. MO3.13 cells stained with C10 (A and C) and C11 red lysosomal probe (B, D, E, F, G 
and H). All samples were stained with blue DAPI to show nuclei. A, B, C and D are 1% EtOH 
vehicle at 60x (A and B) and 100x (C and D). E and G are 2 mM SA CPZ at 60x (A) and 100x 
(C). F and H are 2 mM Gojira CPZ at 60x (B) and 100x (D). Scale bar for all image is set to 50 
µm. 
 
Vehicle         Vehicle 2 mM SA 2 mM Gojira 
60x 
100x 
   
 The treatment of SA CPZ vs Gojira CPZ made no significance difference in the 
lysosomal morphology of the cells. The cells treated with CPZ exhibited more intense 
fluorescence of lysosomes around the nucleus compared to the EtOH treated cells without CPZ 
(Figure 14). This suggests that lysosome production is upregulated under CPZ toxicity to 
account for increased autophagy related signals.  
The 2 mM SA CPZ was imaged with both C10 and C11 lysosomal probes (Figure 15). 
Similar to the EtOH treatment, it was observed that the C10 probe, originally not proven to work 
in fixed cells, appears slightly sharper than the C11 probe. The difference isn’t drastic, but it is 
noticeable (Figures 14 and 15). The cells that were not treated with EtOH or CPZ had similar 
morphology to the treatment cells, however similar to the EtOH treated cells, the lysosomes 
appear to have a wider distribution (Figure 15).  
  
Figure 15. . MO3.13 cells stained with C10 (A, C, E and G) and C11 red lysosomal probe (B, D 
and F). All samples were stained with blue DAPI to show nuclei. A, B, C and D are 1% EtOH 
vehicle at 60x (A and B) and 100x (C and D). E and G are 2 mM SA CPZ at 60x (E) and 100x 
(G). F is MO3.13 cells with no treatment at 60x. Scale bar for all image is set to 50 µm. 
 
This experiment provided an insight on the morphology and pathology of lysosomes 
during CPZ toxicity. Although differences between the treatment groups and control groups were 
Vehicle         Vehicle 2 mM SA        Control 
60x 
100x 
   
miniscule, there were slight differences seen in the distribution and localization of the lysosomes; 
The CPZ treated cells had a higher concentration of lysosomes localized around the nucleus than 
that of the vehicle and control. The microarray data supports that lysosomal and mitochondrial 
function is disrupted by CPZ toxicity. The images of the 2 mM CPZ treatments show slight 
increases in intensity of the lysosomal probe signal, as well as more concentration localization 
around the nucleus. Taken from this, it is possible that the introduction of CPZ upregulates 
lysosomal production by disrupting lysosomal and mitochondrial function, thus increasing 
autophagy related pathways.  
Conclusion 
The neurotoxic effects of cuprizone allow it to be used as a common model of 
demyelination and simulator of neurodegenerative disease both in vivo and in vitro.6,20 The 
human MO3.13 oligodendrocyte cell line exhibits alterations to normal metabolism among 
introduction to CPZ.20 Through this model, further effects of CPZ on neurotoxicity were 
examined in this experiment using MO3.13s as a model. CPZ is most known for its ability to 
chelate copper, however it was previously unclear whether or not CPZ could chelate the 
neighbor of copper on the periodic table, zinc. The results from the CPZ chelation experiment 
suggest that CPZ does not chelate zinc as efficiently as it does copper, however zinc may perturb 
the efficiency of copper-CPZ chelation (Figures 5-7). This experiment also discovered advances 
in CPZ solubility with a decreased percentage of EtOH needed for CPZ to fully dissolve (Figure 
8). With this, the vehicle in cell experiments will be much less likely to cause variation in the 
treatment. The microarray data obtained from CPZ treatment of 6 hours and 9 hours show 
extreme disruption in major lysosomal and mitochondrial pathways, including mTOR, ETC, and 
autophagy (Figures 9-12). Cumulatively, this data demonstrates the crosstalk between lysosomal 
   
and mitochondrial regulation, and how CPZ can perturb normal signaling. The supplementation 
of leucine to rescue cells from CPZ toxicity was also tested in this experiment (Figure 13). 
Overall, the results of the viability assays were not conducive, however they provide direction 
for further experiments. The lowest treatment concentration, 0.2 mM of leucine had the highest 
cell viability, higher than CPZ treatment alone (Figure 13). To further test leucine initiated cell 
rescue from CPZ, a wider range of leucine treatment concentrations can be tested to narrow the 
ideal treatment concentration for rescue. Lysosomal imaging using C10 and C11 probes provided 
information on localization and morphology of lysosomes when subjected to CPZ (Figures 14 
and 15). Although differences were slight, overall, CPZ treated cells exhibited increased 
lysosome localization around the nucleus and increased intensity. This data suggests that CPZ 
may upregulate lysosome production. For all experiments, both Sigma Aldrich and Gojira brand 
CPZ were used. There were no observable differences between the two brands of CPZ. Taken 
altogether, this experiment has provided new advancements in CPZ solubility and has provided 
evidence that introduction of CPZ can cause lysosomal and mitochondrial dysfunction which 
ultimately leads to increased cell death through autophagy. 
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Appendix 1 
Safety Considerations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
All experiments in this lab were conducted in a ventilated hood with gloves following safety 
protocol. All reagents were sterilized with 70% EtOH before entering the hood and after leaving 
the hood. The hood was sprayed with 70% EtOH before and after use. After every experiment in 
the hood, the UV light was turned on for 10 minutes to sterilize. All waste from cell culture 
experiments were neutralized with 50% bleach before discarding in biohazard waste. To reduce 
the risk of contamination, the water bath, incubator and sonicator were routinely cleaned with 
70% EtOH every week and replaced with autoclaved water if necessary. Some reagents that were 
used in this lab are toxic substances. Goggles and a face mask were used when weighing harmful 
chemicals such as paraformaldehyde.  Cuprizone is a toxic chemical that can be harmful if 
ingested. This chemical was handled with gloves in a well ventilated area. Paraformaldehyde is a 
preservative that is toxic to humans. Paraformaldehyde was handled under a hood. Sodium 
Hydroxide and Hydrochloric acid were used to adjust the pH of solutions. These chemicals can 
cause burns if exposed to skin. Gloves were used when dealing with these solutions in the hood. 
The protease, Trypsin, was used to cleave cells from the culture plates. Trypsin is a lysing agent. 
It was strictly used in the hood with gloves on. All utensils that were used in cell experiments 
were autoclaved after use. Before and after lab work, hands were washed to decrease 
contamination. The lab that the research was conducted in is equipped with a safety shower, a 
fire extinguisher and a first aid kit. All of these safety devices were made accessible during 
experiments. 
 
 
 
